Badgley, Phelps & Bell’s Biogen BIIB Stock Holding History

Badgley, Phelps & Bell’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,638	Closed	-$449K	–	180
2018 Q1	$449K	Buy	1,638 +26	+2%	+$8.07K	0.03%	142
2017 Q4	$514K	Buy	+1,612	New	+$517K	0.04%	140

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Badgley, Phelps & Bell's BIIB Position: Q2 2018 in Review

Badgley, Phelps & Bell sold out of Biogen (BIIB) in Q2 2018, closing a stake of 1,638 shares — an estimated $449K sold.

Badgley, Phelps & Bell first reported a position in BIIB in Q4 2017 and held it in 2 quarters. The position peaked at $514K in Q4 2017. 1,097 funds tracked by Wall St. Rank hold BIIB as of Q2 2018.

Badgley, Phelps & Bell reported no remaining Biogen position as of Q2 2018 after selling out during the quarter.
Badgley, Phelps & Bell sold 1,638 Biogen shares in Q2 2018, an estimated $449K.
Badgley, Phelps & Bell first reported a position in Biogen in Q4 2017 and held it in 2 quarters.
Badgley, Phelps & Bell's Biogen position peaked at $514K in Q4 2017.
1,097 funds tracked by Wall St. Rank held Biogen as of Q2 2018.

Based on Badgley, Phelps & Bell's 13F filing for Q2 2018, filed 30 Jul 2018.